CatalystFDA/Bio

MERCK PULLS BLA FOR ANTIBODY-DRUG CONJUGATE I-DXD FOR SMALL CELL LUNG CANCER - SEEKINGALPHA

Merck's BLA withdrawal for I-DXd in small cell lung cancer signals regulatory setback.

What changed

Merck's BLA withdrawal for I-DXd in small cell lung cancer signals regulatory setback.

Why it matters

Merck's BLA withdrawal for I-DXd in small cell lung cancer signals regulatory setback. — impact context not separately stored; see What changed.

Sources